Vertex Pharmaceuticals

Healthcare | Biotechnology | USA
This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales

Late Tuesday, Vertex Pharmaceuticals (VRTX) topped fourth-quarter sales and earnings forecasts as revenue from the biotech's cystic fibrosis treatments jumped by 40%. Vertex stock rose in late action.

For the fourth quarter, Vertex earnings of $1.30 per share, minus certain items, spiked 113% year over year. That beat estimates from analysts polled by Zacks Investment Research, which called for Vertex earnings of $1.05 per share, on an adjusted basis.

Total revenue popped nearly 34% to $870.11 million. 

...

https://www.investors.com/news/technolog...yptr=yahoo

VRTX nachbörslich +2,6 % auf 192

Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates

Vertex Pharmaceuticals Incorporated VRTX delivered third-quarter 2019 earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.14. Moreover, earnings rose 13% year over year. Strong cystic fibrosis (CF) product revenues led to higher profits in the reported quarter.

However, Vertex’s revenues of $949.8 million missed the Zacks Consensus Estimate of $952 million. But the company’s sales increased 21.1% year over year, driven by the rapid uptake of its newest CF medicine Symdeko in the United States. Symdeko is marketed under the trade name Symkevi in the EU.



...


https://finance.yahoo.com/news/vertex-vr...04528.html

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.30 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 40.50%. A quarter ago, it was expected that this drugmaker would post earnings of $1.14 per share when it actually produced earnings of $1.23, delivering a surprise of 7.89%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Vertex, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.41 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 41.36%. This compares to year-ago revenues of $870.11 million.


...

https://finance.yahoo.com/news/vertex-ph...10940.html

Why Vertex Pharmaceuticals Stock Is Slumping Today

Investors are concerned about Vertex's pipeline after a rare miss in the clinic.

What happened

Shares of rare-disease specialist Vertex Pharmaceuticals (NASDAQ:VRTX) fell by as much as 15.7% in pre-market trading Thursday morning. The biotech's stock is under pressure today due to a worrying safety signal observed in a midstage trial for the small-molecule drug VX-814 as a potential treatment for alpha-1 antitrypsin deficiency (AATD). 

...


https://www.fool.com/investing/2020/10/1...ing-today/

Trotz magerer Kapitalgewinne bei ihren Beteiligungen in der Gesundheitsbranche hat Cathie Wood ihre Positionen beibehalten, weil sie erwartet, dass sich die Genomik im Jahr 2021 als nächster großer Sektor herauskristallisieren wird, der ähnliche Gewinne wie die Elektrofahrzeugbranche (EV) liefern könnte. So sind Novartis (NVS), Vertex Pharmaceuticals (NASDAQ:VRTX) und Regeneron Pharmaceuticals (REGN) mit ihren Fortschritten auf dem Gebiet der Therapeutika und der Krebsforschung die Top-Holdings in Woods Genomic Revolution (ETF). Die renommierte Investorin Cathie Wood hat seit langem ein großes Interesse an der Gesundheitsbranche und setzt dabei auf die Genomische Revolution


https://stocknews.com/news/nvs-vrtx-regn...portfolio/

Vertex Pharmaceuticals

Sales of cystic fibrosis treatments from Vertex Pharmaceuticals (NASDAQ: VRTX) are on pace to pass $10 billion annually, but investors want to see the company expand beyond an indication that only affects around 105,000 people globally.

To help expand its addressable market, Vertex finished September on pace to spend more than $3 billion on research and development in 2023. Soon, investors will see if an important portion of that research can pay off.

In early 2024, Vertex is expected to share results from two studies with VX-548. This is a new, non-opioid pain-relief candidate that inhibits NaV1.8, a protein that plays a crucial role in sending pain signals to the brain.

Last November, Vertex said it had already finished a phase 3 trial with VX-548 as an acute pain reliever for patients following "tummy tuck" procedures. Another phase 3 trial with patients who just had bunions removed from their feet has likely wrapped up as well.

A new way to treat chronic and acute pain could bring in billions for Vertex, but success in phase 3 is far from guaranteed. Pain is hard to measure, and trials designed to measure pain relief are highly subject to a placebo effect. This combination of challenges makes developing new pain drugs a risk that most drugmakers avoid.

Shares of Vertex are up more than 40% over the past year thanks to the recent approval of the first therapy from its collaboration partner, CRISPR Therapeutics. The rally pushed its valuation up to 24.9 times forward-looking earnings expectations.

Vertex Pharmaceutical's valuation appears reasonable when you consider how rapidly sales of its cystic fibrosis drugs have grown so far. Looking ahead, though, there aren't enough untreated patients available to continue growing at the same pace.

Vertex's pain-relief program could produce results that push the stock higher, but the stock presents a level of risk that should convince cautious investors to keep looking for better ideas.

https://finance.yahoo.com/m/8ff4c26f-7ae...-huge.html